Stockscreener 앱 받기
14.30
4.38%
0.60
시장 영업 전:
14.54
0.24
+1.68%
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Mineralys stock holds Buy rating at H.C. Wainwright after CKD trial - Investing.com Canada
Mineralys enhances lorundrostat data package ahead of planned NDA - The Pharma Letter
Mineralys Therapeutics (MLYS): Analyst Reiterates Buy Rating and Price Target | MLYS Stock News - GuruFocus
Promising Trial Results for Lorundrostat Boost Mineralys Therapeutics’ Investment Appeal - TipRanks
Mineralys reports positive phase 2 data for lorundrostat in CKD By Investing.com - Investing.com South Africa
Mineralys reports positive phase 2 data for lorundrostat in CKD - Investing.com Australia
Mineralys Therapeutics Shares Climb on Strong Results from Kidney Disease Trial - MSN
Positive Phase II Results for Mineralys Therapeutics’ Lorundrostat Support Buy Rating - TipRanks
Promising Phase 2 Trial Results for Mineralys Therapeutics’ Lorundrostat Support Buy Rating and $42 Price Target - TipRanks
Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps - Benzinga
Transcript : Mineralys Therapeutics, Inc.Special Call - MarketScreener
Mineralys Therapeutics stock jumps after positive kidney disease trial data By Investing.com - Investing.com South Africa
Mineralys Therapeutics' Phase 2 Explore-CKD Study Of Lorundrostat Meets Primary Goal - Nasdaq
Mineralys Phase 2 Trial of Hypertension, Kidney Disease Drug Meets Primary Endpoint; Shares Up Pre-Bell - MarketScreener
Mineralys Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria - GlobeNewswire
Breakthrough: Mineralys Phase 2 Drug Achieves Dual Success in Blood Pressure and Kidney Protection Trial - Stock Titan
How the (MLYS) price action is used to our Advantage - news.stocktradersdaily.com
Mineralys Therapeutics (NASDAQ:MLYS) Cut to Sell at Wall Street Zen - Defense World
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Jefferies Initiates Coverage on Mineralys Therapeutics (MLYS) with Hold Rating | MLYS Stock News - GuruFocus
Jefferies Initiates Coverage on Mineralys Therapeutics With Hold Rating, $15 Price Target - MarketScreener
Jefferies initiates Mineralys Therapeutics stock with hold rating By Investing.com - Investing.com Nigeria
Jefferies initiates Mineralys Therapeutics stock with hold rating - Investing.com
Cautious Outlook for Mineralys Therapeutics Amid Market Challenges and Competitive Pressures - TipRanks
Bank of America Corp DE Has $1.33 Million Stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
BNP Paribas Financial Markets Buys Shares of 3,895 Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics: Merits A Small 'Speculative' Holding (NASDAQ:MLYS) - Seeking Alpha
ProShare Advisors LLC Takes Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Purchased by Deutsche Bank AG - Defense World
Mineralys Therapeutics Reveals Promising Phase 3 Results for Hypertension Drug Lorundrostat - MSN
Mineralys Therapeutics to Present Phase 3 Data on Lorundrostat at European Hypertension Meeting - MSN
Mineralys announces late-breaking presentation of data from Launch-HTN trial - Yahoo Finance
Buy Rating for Mineralys Therapeutics: Strong Clinical Results and Growth Prospects Highlight Significant Upside Potential - TipRanks
Mineralys reports outcomes from trial of lorundrostat for hypertension - Yahoo Finance
MLYS: Promising Phase 3 Results for Hypertension Treatment | MLYS Stock News - GuruFocus
Northern Trust Corp Purchases 1,688 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) - The Manila Times
Mineralys Therapeutics Reports Positive Results from Phase 3 Launch-HTN Trial of Lorundrostat for Uncontrolled Hypertension - Nasdaq
These 3 Artificial Intelligence (AI) Stocks Look Cheap Right Now - The Globe and Mail
Mineralys Therapeutics Inc Says Lorundrostat Shows 16.9 Mmhg Reduction At Week 6, 19.0 Mmhg At Week 12 - marketscreener.com
Mineralys Therapeutics Announces Late-Breaking Presentation - GlobeNewswire
Breakthrough Phase 3 Results: New Drug Cuts Blood Pressure by 19 mmHg in Largest Hypertension Trial - Stock Titan
Mineralys Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going - sharewise
Mineralys to present lorundrostat trial data at ESH 2025 - Investing.com Australia
Mineralys to present lorundrostat trial data at ESH 2025 By Investing.com - Investing.com South Africa
Mineralys Announces Late-Breaking Presentation Of Phase 3 Launch-HTN Trial - marketscreener.com
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection - The Manila Times
1.45%
0.86%
자본화:
|
볼륨(24시간):